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Background: Resistance to carbapenem antibiotics is emerging worldwide among Enterobacteriaceae. To prevent
hospital transmission due to unnoticed carriage of carbapenemase producing micro-organisms in newly admitted
patients, or follow-up of patients in an outbreak setting, a molecular screening method was developed for
detection of the most prevalent carbapenemase genes; blaOXA-48, blaVIM, blaIMP, blaNDM and blaKPC.
Methods: A real-time multiplex PCR assay was evaluated using a collection of 86 Gram negative isolates, including
62 carbapenemase producers. Seven different laboratories carried out this method and used the assay for detection
of the carbapenemase genes on a selection of 20 isolates.
Results: Both sensitivity and specificity of the multiplex PCR assay was 100%, as established by results on the strain
collection and the inter-laboratory comparisons.
Conclusions: In this study, we present a multiplex real-time PCR that is a robust, reliable and rapid method for the
detection of the most prevalent carbapenemases blaOXA-48, blaVIM, blaIMP, blaNDM and blaKPC, and is suitable for
screening of broth cultured rectal swabs and for identification of carbapenemase genes in cultures.
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Carbapenemase producing Enterobacteriaceae (CPE) are
emerging worldwide, and have been implicated in nu-
merous outbreaks [1-3]. Rapid and accurate detection of
CPE is pivotal for adequate antibiotic therapy and infec-
tion control, especially in an outbreak setting. The most
commonly used phenotypic CPE confirmation tests, the
modified Hodge test and the carbapenemase inhibition
tests with boronic acid or EDTA/DPA, have several disad-
vantages, because those tests require an overnight incuba-
tion step, do not provide information on the carbapenemase
gene, and cannot differentiate OXA-48 producing isolates
from ESBL and/or AmpC producing isolates with decreased
permeability [4-7]. Finally, phenotypic detection of CPE* Correspondence: Zeea@maasstadziekenhuis.nl
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article, unless otherwise stated.may be difficult because carbapenem MICs may be low
(in the susceptible range), especially of OXA-48 produ-
cing Enterobacteriaceae. Therefore, genotypic detection
of carbapenemase genes is the gold standard, although
it only detects a pre-specified set of known genes. Here,
we describe a real-time PCR for detection of NDM,
KPC, VIM, IMP and OXA-48 genes, which are currently
the most prevalent carbapenemases [8]. The main goal
of this study was optimization of this real time PCR and
to determine the test characteristics on a set of well
characterized isolates. An interlaboratory performance
comparison of the PCR assay was initiated to investigate
its robustness and reliability.Methods
PCR design
We developed specific real-time PCRs for detection of KPC,
VIM, NDM, OXA-48 and IMP. For design of the primers,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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www.lahey.org/Studies were taken into account, along with
synonymous mutations (Additional file 1: Table S1). Detec-
tion of CTX-M [9] was included for optional use since it
complements OXA-48 for resistance to extended spectrum
cephalosporins, a characteristic that is intrinsic to the other
carbapenemases. For verification of newly designed PCRs,
sequencing was done on larger gene fragments. For NDM
sequencing primers 5′-GCGAAAGTCAGGCTGTGTTG-
3, and ‘5′-CATTAGCCGCTGCATTGATG-3′, were
used, and for IMP sequencing primers 5′-GGCGGAATA
GAGTGGCTTAATTCTC-3′, and 5′-CGTACGGTTTAA
CAAAACAACCACC-3′ For each separate carbapenemase
gene, PCR primers and probe concentrations were op-
timized. Multiplex combinations were compared with
single PCRs in presence of the internal control Phocine
Herpes Virus (PhHV).Bacterial strains
PCRs were optimized and validated using the following
control strains: a KPC producing Klebsiella pneumonia,
a VIM-2 producing Pseudomonas aeruginosa, an IMP-
18 producing P. aeruginosa, an IMP-28 producing K.
pneumoniae, a NDM-1 positive K. pneumoniae, and an
OXA-48 positive K. pneumoniae isolate.
Testing of PCR specificity was carried out on the
following strain collection. The test collection of 86
isolates, included 58 carbapenemase producing isolates,
and 28 carbapenemase negative controls. The 58 carbape-
nemase positive isolates consisted of 45K. pneumoniae, 4
E. coli, 3 Enterobacter species, 2 P. mirabilis, 2 Citrobacter
species, and 2 P. aeruginoasa isolates producing the
following carbapenemases: 20 KPC-2/3, 4 KPC plus
VIM, 21 VIM, 4 NDM-1, 2 IMP, and 7 OXA-48. The
28 carbapenemase negative controls consisted of 10 K.
pneumoniae, 2 E. coli and 16 Enterobacter isolates,
producing either an ESBL (20 isolates) or an AmpC
beta-lactamase (Additional file 2: Table S2). As the ref-
erence test for presence of beta-lactamases, PCR and
sequencing was used [10].PCR evaluation
To determine the sensitivity and specificity of PCR, 86
unrelated test isolates were investigated both from agar
plate and broth. Two protocols were followed; protocol
1) simultaneous multiplex detection of OXA-48, VIM,
IMP, NDM and KPC. In this PCR reaction, the OXA-
48 probe was labelled with FAM, and the other carba-
penemases with VIC. Protocol 2) 3 multiplex PCRs for
identification of respectively OXA-48/CTX-M, VIM/IMP,
and NDM/KPC. PhHV was labelled with NED. Fluorescent
labels of carbapenemase genes were FAM, and VIC, re-
spectively (Additional file 3: Table S3).PCR
Strains were grown on MacConkey agar (Oxoid), and in
Brain Heart broth, both supplemented with ertapenem
(0.125 mg/l). One colony was taken from the plate and
50 μl from the broth. Both were suspended in 100 μl
Extraction Solution (SIGMA, E7526). Mixtures were incu-
bated at 95°C for 10 minutes, cooled to room temperature,
100 μl Dilution Buffer (SIGMA, D5688) was added and
mixed. PCR reactions were carried out using PCR-
ReadyMix™ (SIGMA, E3004). Amplification was performed
on ABI 7500 Real-Time PCR system (LifeTech, Glasgow,
UK). The temperature profile included initial denatur-
ation of 4 min. at 94°C, followed by 50 cycles (40 cycles,
protocol 2) of 94°C for 15 sec., and 60°C for 1 min.
Results
Evaluation of PCR
PCRs on serial dilutions of template showed Cq (Cycle
threshold) values ranging from 19.5-41.5 for single PCRs,
and Cq values of 20.2-46.3 for multiplex reactions. The
mean difference in Cq value between single and multiplex
reactions was 0.9, with a tendency towards an increased dif-
ference with decreasing template concentrations. Mixing of
templates did not affect Cq values. The lower limit of detec-
tion was approximately 10 colony forming units. The amp-
lification efficiencies in multiplex format ranged from 85%
for VIM to 82% for IMP (Figure 1). We concluded that the
PCRs were compatible.
The PCR assay according to protocol 1 was carried
out on the test collection of 86 strains (Additional file 2:
Table S2). All carbapenemase producing isolates were
positive in the PCR with Cq values ranging from 15.4 to
23 for isolates from agar, and Ct values 20.1 to 28 from
broth cultures (Figure 2A), corresponding to a sensitivity
of 100%. All 26 carbapenemase negative control isolates
were negative in the PCR, corresponding to a specificity
of 100%.
To evaluate the capacity of the real-time PCR to iden-
tify carbapenemase genes, protocol 2 was used. Twenty-
five strains were PCR positive for VIM, 2 for IMP, 4 for
NDM, 24 for KPC, 7 for OXA-48 and 18 for CTX-M.
Four strains were positive for both VIM and KPC and 2
strains both for OXA-48 and CTX-M (Figure 2B). Ct
values ranged from 15.1-22.5 (VIM), 13.2-20.6 (KPC),
17.8-20.1 (NDM), 16.8-23.8 (OXA-48) and, 14.7-17.2
(CTX-M). The results were 100% concordant with listed
strain characteristics.
Multi-centre comparison
The PCR assay (protocol 2) was tested on a selection of
20 strains (Table 1) by 7 different laboratories. Different
PCR platforms were used; ABI7500 (Life Technologies),
RotorgeneQ (Qiagen), Biorad CFX96 (Bio-Rad), and
Lightcycler 480 (Roche). Also different DNA polymerases
Figure 1 Standard curve of multiplex PCR. Inferred efficiencies of multiplex amplification range from 82% for IMP, to 85% for VIM.
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PCR Master Mix (Life Technologies), Fast start master
(Roche), and Master Mix for PCR (Bio-Rad). All laborator-
ies correctly detected the targeted carbapenemase genes,
and no false positive results were found. With exception
of CTX-M, which was not tested, or partially tested as is
shown in Table 1, results of the multi-centre comparison
were all concordant and again, the results were 100%
concordant with listed strain characteristics.
Thus, both inter- and intra-laboratory, PCR sensitivity
and specificity corresponds to 100%. Two laboratories
also subjected the 20 control strains to Check-points
PCR assay (laboratory 3) and Check-MDR Carba Assay
(laboratory 6). The results were concordant with our
PCR assay, except that In the Check-MDR Carba Assay
IMP-28 was missed.Figure 2 A) Amplification plot of VIC labelled PCR products of VIM, N
(protocol 2). Reactions were performed in the presence of the internal co
with lower plots were also positive for CTX-M.Discussion
This assay has several advantages. First, it is able to de-
tect the five most prevalent carbapenemases, whereas
previously published real-time PCRs for detection of
carbapenemases were designed to detect either exclusively
KPC, or exclusively NDM, or a combination of GES,
IMI/NMC, KPC, OXA-48 and SME [11-14]. Second, the
good performance of the assay when using pre-cultured
broth, makes this method suitable for detection of car-
bapenemases in clinical swabs.
The PCR assays described here were designed to
predominantly detect OXA-48 in the follow-up of an
outbreak. The PCR assay according to protocol 1
therefore can only detect if one of the other carbapene-
mases (except OXA-48) is present or not. The probes
of the other carbapenemases can also be differentiallyDM, and KPC (protocol 1), and B) OXA-48/CTX-M and VIM/IMP
ntrol PhHV. For clarity, a selection of strains is shown. OXA-48 positives
Table 1 Multi-centre comparison of the PCR assay for detection of carbapenemases, and the PCR platforms, and DNA
polymerases used
Strain ID Laboratory1 Laboratory2 Laboratory31 Laboratory41 Laboratory52 Laboratory62 Laboratory72
OXA 8-90 OXA-48 OXA-48 OXA-48 OXA-48 OXA-48 OXA-48 OXA-48
OXA 8-17 OXA-48/CTX-M OXA-48/CTX-M OXA-48/CTX-M OXA-48/CTX-M OXA-48 OXA-48 OXA-48
S 4-2 OXA-48/CTX-M OXA-48/CTX-M OXA-48/CTX-M OXA-48/CTX-M OXA-48 OXA-48 OXA-48
S3-60 OXA-48/CTX-M OXA-48/CTX-M OXA-48/CTX-M OXA-48/CTX-M OXA-48 OXA-48 OXA-48
GR-21/PM-302 VIM VIM VIM VIM VIM VIM VIM
GR-04/KP-69 VIM/KPC VIM/KPC VIM/KPC VIM/KPC VIM/KPC VIM/KPC VIM/KPC
GR-38/KP-139 VIM VIM VIM VIM VIM VIM VIM
GR-31/KP-956 VIM/KPC VIM/KPC VIM/KPC VIM/KPC VIM/KPC VIM/KPC VIM/KPC
GR-23/KP-385 KPC KPC KPC KPC KPC KPC KPC/imp*
New York-11 KPC KPC KPC KPC KPC KPC KPC
New York-3 KPC KPC KPC KPC KPC KPC KPC
JS022 NDM/CTX-M NDM/CTX-M NDM/CTX-M NDM/CTX-M NDM NDM NDM
RC-89 NDM/CTX-M NDM/CTX-M NDM/CTX-M NDM/CTX-M NDM NDM NDM
S 3-62 IMP IMP IMP IMP IMP IMP IMP
S5-36 IMP IMP IMP IMP IMP IMP IMP
RC-79 CTX-M CTX-M CTX-M CTX-M negative negative negative
EIE-UMC-1 CTX-M CTX-M negative negative negative negative negative
RC-8 negative negative negative negative negative negative negative
RC-16 negative negative negative negative negative negative negative
GR-07/KP-3878 negative negative negative negative negative negative negative
thermocycler Biorad CFX LC 480 ABI 7500 ABI 7500 LC 480 ABI 7500 LC 480
Biorad CFX
polymerase Sigma Roche ABI ABI Roche N-Amp Roche
Biorad
1 Only CTX-M group I PCR was performed.
2 No CTX-M PCR was performed.
*: Background IMP was detected, and scored as inconclusive by laboratory 7.
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and identify the genes. This is however limited to 3–4
different labels in addition to that of the internal con-
trol, and depends on the spectral specifics of the type
of thermocycler.
Multi-centre evaluation of the assay showed concordant
results, which demonstrates that the test is robust and can
be performed in different laboratories using different amp-
lification platforms and/or DNA polymerases.
The PCR detection of the IMP gene still requires at-
tention. Check-Points also has withdrawn detection of
IMP from their latest kit. Although we designed two
probes that in theory can detect all IMP variants, we
have not been able to test whether this is indeed the
case. This will be subject for future study.
An intrinsic limitation of this type of assay is that new
carbapenemase families or new variants of known fam-
ilies may not be detected. The flexibility of the system
presented here, however, allows easy adaptation. For
example, detection of other genes e.g. PER or GES, might
be added to this multiplex PCR.Conclusions
The multiplex real-time PCR described here is a robust,
reliable and rapid method for detection of the most
prevalent carbapenemase genes blaOXA-48, blaVIM, blaIMP,
blaNDM and blaKPC.
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